Redefining Liver Health Through Early Detection and Monitoring: A Paradigm Shift
HeparDx: A blood test for MASH and Liver Fibrosis focused on detecting lobular inflammation and hepatocyte ballooning
In June 2023, the American Diabetes Association Recommended that all Type 2 Diabetes patients are screened for MASLD (NAFLD).
In June 2023, the multinational liver societies AASLD, EASL and ALEH announced a change in nomenclature for the diseases formerly described as NAFLD and NASH. Nonalcoholic fatty liver disease (NAFLD) is now metabolic dysfunction-associated steatotic liver disease (MASLD); metabolic dysfunction-associated steatohepatitis (MASH) is the replacement term for nonalcoholic steatohepatitis (NASH).